Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2824-2830

  Hadwiger, Michael E ^a   Sommers, Cynthia D ^a   Mans, Daniel J ^a   Patel, Vikram ^a   Boyne II, Michael T ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ARTICLE; ASSAY; CONTROLLED STUDY; DIODE; DRUG IMPURITY; DRUG POTENCY; DRUG QUALITY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; UNITED STATES;

CHROMATOGRAPHY, LIQUID; CONSUMER PRODUCT SAFETY; MASS SPECTROMETRY; QUALITY CONTROL; UNITED STATES; VANCOMYCIN;

EID: 84861172983     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00164-12     Document Type: Article

References (21)

1. Bosso JA, et al. 2011. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob. Agents Chemother. 55:5475-5479.
2. Bozdag S, et al. 2010. In vitro evaluation of gentamicin- and vancomycin-containing minitablets as a replacement for fortified eye drops. Drug Dev. Ind. Pharm. 36:1259-1270.
3. British Pharmacopoeia. 2012. Vancomycin intravenous infusion. British pharmacopoeia, vol III. TSO, Norwich, United Kingdom.
4. Diana J, Visky D, Hoogmartens J, Van Schepdael A, Adams E. 2006. Investigation of vancomycin and related substances by liquid chromatography/ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 20:685-693. (Pubitemid 43236858)
5. Diana J, Visky D, Roets E, Hoogmartens J. 2003. Development and validation of an improved method for the analysis of vancomycin by liquid chromatography selectivity of reversed-phase columns towards vancomycin components. J. Chromatogr. A 996:115-131. (Pubitemid 36627797)
6. Fischbach MA, Walsh CT. 2006. Assembly-line enzymology for polyketide and nonribosomal peptide antibiotics: logic, machinery, and mechanisms. Chem. Rev. 106:3468-3496. (Pubitemid 44376945)
7. Haghedooren E, Diana J, Noszal B, Hoogmartens J, Adams E. 2007. Classification of reversed-phase columns based on their selectivity towards vancomycin compounds. Talanta 71:31-37. (Pubitemid 46043492)
8. Harris CM, Kopecka H, Harris TM. 1983. Vancomycin: structure and transformation to CDP-I. J. Am. Chem. Soc. 105:6915-6922.
9. Kahne D, Leimkuhler C, Lu W, Walsh C. 2005. Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. 105:425-448. (Pubitemid 40356089)
10. Lodise TP, Lomaestro B, Graves J, Drusano GL. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52:1330-1336. (Pubitemid 351521995)
11. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
12. Marshall FJ. 1965. Structure studies on vancomycin. J. Med. Chem. 8:18-22.
13. Murray BE. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342:710-721. (Pubitemid 30131425)
14. Nambiar S, et al. 2012. Product quality of parenteral vancomycin products in the United States. Antimicrob. Agents Chemother. 56:2819-2823.
15. Nolan EM, Walsh CT. 2009. How nature morphs peptide scaffolds into antibiotics. Chembiochem 10:34-53.
16. Plock N, Buerger C, Kloft C. 2005. Successful management of discovered pH dependence in vancomycin recovery studies: novel HPLC method for microdialysis and plasma samples. Biomed. Chromatogr. 19:237-244. (Pubitemid 40528591)
17. Somerville AL, Wright DH, Rotschafer JC. 1999. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 19:702-707. (Pubitemid 29277969)
18. USP. 2011. Antibiotics - microbial assays. United States pharmacopeia and national formulary, vol USP 34-NF 29. USP, Rockville, MD.
19. USP. 2011. Vancomycin hydrochloride for injection. United States pharmacopeia and national formulary, vol USP 34-NF 29. USP, Rockville,MD.
20. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54:3271-3279.
21. Yang H, Zubarev RA. 2010. Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides. Electrophoresis 31:1764-1772.